|
|
|
Expert Perspectives on Clinical Practice
|
|
|
Daily Clinical Updates and Downloadable Slides: Critical Analysis of Key Data from the 2011 Annual Multidisciplinary Cancer Meeting in Stockholm, Sweden
|
|
|
|
|
Expert Interviews |
 |
Downloadable slides |
 |
|
 |
Release Date
September 29, 2011
|
Expiration Date
September 29, 2012 |
|
| Faculty |
Federico Cappuzzo, MD
Ospedale Civile di Livorno
Livorno, Italy
Lee Krug, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Sunil Verma, MD, MSEd, FRCPC
Sunnybrook Odette Cancer Center
Toronto, Ontario, Canada
|
|
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists,
radiologists, and other healthcare providers involved and/or interested in the care of patients with
mesothelioma and non-small cell lung cancer (NSCLC).
|
Overview
This CME-certified interview covers recently released data from the 2011 Annual Multidisciplinary Cancer Meeting in Stockholm, Sweden, focusing on mesothelioma and NSCLC.
|
Learning Objectives
After successful completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data pertaining to mesothelioma and NSCLC and how these data should be incorporated into current standards of care to improve patient outcomes
- Discuss the rationale and utility of novel agents or combinatorial strategies that may provide superior disease outcomes for patients with mesothelioma and NSCLC compared to current standards of care
- Determine best strategies for integration of targeted therapies into treatment regimens for patients with pleural mesothelioma and NSCLC
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Education
prIME Oncology is accredited by the Accreditation Council of Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this
CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post test are available on the video player page.
|
Support Statements
This activity is supported by unrestricted educational grants from Merck Sharp & Dohme Corporation and Boehringer Ingelheim Pharmaceuticals, Inc. |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Verma has disclosed that he has received consulting fees from Eli Lilly, Roche, and AstraZeneca. He has performed contracted research for Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Cappuzzo has disclosed that he has received consulting fees from GSK and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Krug has disclosed that he has received consulting fees from Genentech. He has performed contracted research for Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Amy Furedy, RN, OCN (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
 |
|
|
|
|
|
